Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (121-130 of 937) with videos related to

Pageof 94
Sort By:
Anticancer Research|September 12, 2013
APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cellsGünter Eisele, Fabian Wolpert, Guillaume Decrey, et al.
Current Neurology and Neuroscience Reports|March 20, 2012
Clinical implications of molecular neuropathology and biomarkers for malignant gliomaGhazaleh Tabatabai, Monika Hegi, Roger Stupp, et al.
Neuro-Oncology|October 24, 2017
Meeting Update-World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017Jaclyn J Renfrow, Michael Weller, Roy E Strowd
Neuro-Oncology|December 24, 2024
Next step towards functional precision medicine in neuro-oncologyTobias Weiss, Sohyon Lee, Berend Snijder, et al.
Chemotherapy|October 27, 2015
Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade GliomaMichaela Tonder, Michael Weller, Günter Eisele, et al.
Current Neurology and Neuroscience Reports|February 1, 2011
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidenceWolfgang Wick, Antje Wick, Markus Weiler, et al.
Cancer Journal (Sudbury, Mass.)|February 1, 2012
Individualized targeted therapy for glioblastoma: fact or fiction?Michael Weller, Roger Stupp, Monika Hegi, et al.
Translational Oncology|December 26, 2022
Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma modelsEvelina Blomberg, Manuela Silginer, Patrick Roth, et al.
Cell Death & Disease|April 21, 2017
Biological activity of tumor-treating fields in preclinical glioma modelsManuela Silginer, Michael Weller, Roger Stupp, et al.
Current Treatment Options in Neurology|December 18, 2013
Treatment of primary CNS lymphomaPatrick Roth, Roger Stupp, Günter Eisele, et al.
Pageof 94

Showing results (121-130 of 937) with videos related to

Sort By:
Pageof 94
Anticancer Research|September 12, 2013
APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cellsGünter Eisele, Fabian Wolpert, Guillaume Decrey, et al.
Current Neurology and Neuroscience Reports|March 20, 2012
Clinical implications of molecular neuropathology and biomarkers for malignant gliomaGhazaleh Tabatabai, Monika Hegi, Roger Stupp, et al.
Neuro-Oncology|October 24, 2017
Meeting Update-World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017Jaclyn J Renfrow, Michael Weller, Roy E Strowd
Neuro-Oncology|December 24, 2024
Next step towards functional precision medicine in neuro-oncologyTobias Weiss, Sohyon Lee, Berend Snijder, et al.
Chemotherapy|October 27, 2015
Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade GliomaMichaela Tonder, Michael Weller, Günter Eisele, et al.
Current Neurology and Neuroscience Reports|February 1, 2011
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidenceWolfgang Wick, Antje Wick, Markus Weiler, et al.
Cancer Journal (Sudbury, Mass.)|February 1, 2012
Individualized targeted therapy for glioblastoma: fact or fiction?Michael Weller, Roger Stupp, Monika Hegi, et al.
Translational Oncology|December 26, 2022
Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma modelsEvelina Blomberg, Manuela Silginer, Patrick Roth, et al.
Cell Death & Disease|April 21, 2017
Biological activity of tumor-treating fields in preclinical glioma modelsManuela Silginer, Michael Weller, Roger Stupp, et al.
Current Treatment Options in Neurology|December 18, 2013
Treatment of primary CNS lymphomaPatrick Roth, Roger Stupp, Günter Eisele, et al.
Pageof 94